A bill to amend title 18, United States Code, to prohibit former employees of covered health agencies from serving on the board of entities involved in development and research of a drug, biological product, or device and from profiting from a drug, biological product, or device, and for other purposes.

5/2/2024, 6:11 AM

Summary of Bill S 4232

Bill 118 s 4232 aims to make changes to title 18 of the United States Code in order to prevent former employees of certain health agencies from serving on the boards of entities that are involved in the development and research of drugs, biological products, or devices. The bill also seeks to prohibit these former employees from profiting from these products. The main goal of this legislation is to prevent any potential conflicts of interest that may arise from former employees using their insider knowledge and connections for personal gain in the pharmaceutical and medical device industries. This bill is designed to promote transparency and integrity in the healthcare sector.

Current Status of Bill S 4232

Bill S 4232 is currently in the status of Bill Introduced since May 1, 2024. Bill S 4232 was introduced during Congress 118 and was introduced to the Senate on May 1, 2024. Bill S 4232's most recent activity was Read twice and referred to the Committee on the Judiciary. as of May 1, 2024

Bipartisan Support of Bill S 4232

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4232

Primary Policy Focus

Alternate Title(s) of Bill S 4232

A bill to amend title 18, United States Code, to prohibit former employees of covered health agencies from serving on the board of entities involved in development and research of a drug, biological product, or device and from profiting from a drug, biological product, or device, and for other purposes.